CVC  MedImmune Ventures

     Office Locations:

One MedImmune Way
Gaithersburg, MD 20878
Phone: 301-398-0000
Fax: 301-398-8170

Get all office locations for this firm with a National Database subscription.


  • Early
  • Expansion
  • Growth



  • Life Sciences & Healthcare



    As a wholly-owned venture capital fund within the AstraZeneca Group, MedImmune Ventures (MV) invests in private companies which develop small and large molecules, vaccines, pharmaceutical technologies and platforms. The firm also seeks investments in medical devices, diagnostics, imaging and healthcare IT which pertain to the discovery, development and commercialization of pharmaceutical products. MV's therapeutic scope is broad, as is its geographic interest. While MV had initially focused on North America, the firm will currently consider companies anywhere in the world where it has strong local relationships. Stage-wise, MV invests in companies with early to late stage products and technologies, in early (e.g. seed) to late (e.g. mezzanine) rounds of financing. With $400M under management in an evergreen fund, MV has invested in over 30 companies since 2002.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Isai Peimer Principal
    Michael Gutch PhD Managing Director
    Ron Laufer MD Senior Managing Director
    Samuel Wu MD, PhD Managing Director
    Tyrell Rivers PhD Senior Associate


    Portfolio companies include:

      Adheron Therapeutics
        web link

        web link

      Ambit Biosciences
        web link

      Applied Genetic Technologies (AGTC)
        web link

        web link

        web link

        web link

        web link

        web link

        web link

        web link

      G1 Therapeutics
        web link

      Hydra Biosciences
        web link

      Inotek Pharmaceuticals
        web link

      Ligocyte Pharmaceuticals
        web link

        web link

        web link

      NKT Therapeutics
        web link

      Rib-X Pharmaceuticals
        web link

        web link

        web link

      VentiRx Pharmaceuticals
        web link

        web link

        web link


    Recent News: